SiPhox Health, the leader in building the next generation of lab-grade home health testing with silicon photonics, raised $27 million in funding including a $10M Seed financing and a $17M Series A round. The
Series A round was led by Intel Capital with participation from Khosla Ventures, Kortex
Ventures, Alumni Ventures, Metaplanet, Shorewind Capital, LongeVC, Overlap Holdings and
Duke Capital Partners. The Seed funding was led by Khosla Ventures and Y Combinator with
participation from Metaplanet, Massachusetts Manufacturing Innovation Initiative, Rsquared,
Vituity, Paul Buchheit, Balaji Srinivasan, Bob Lee, and Longevity Tech Fund among others.
Intel Capital managing director Srini Ananth will also join SiPhox Health’s board of directors
to further accelerate the company’s growth.
Six out of ten Americans are living with a chronic disease. Access to low-cost, convenient
health testing can help prevent and manage these conditions, improving the lives of patients
and enabling many healthcare innovations that are bottlenecked by existing testing
approaches. In response to this crisis, MIT scientists Diedrik Vermeulen and Michael
Dubrovsky had a vision of using silicon photonics, the semiconductor technology that
transformed internet connectivity, to put a lab-grade health testing device in every home.
“At SiPhox Health, we are leveraging the trillions of dollars invested in the semiconductor
industry to enable lab-quality results in a consumer-ready, user-friendly device,” explained
Diedrik Vermeulen, SiPhox Health co-founder and CEO, and a silicon photonics pioneer who
played a crucial role in developing the first coherent silicon photonic transceiver chip, now
responsible for a significant share of global internet traffic.
The Series A funding will enable team expansion as SiPhox Health works towards FDA
clearance for its SiPhox Home platform, which will offer a broad menu of proteins and
hormone tests from a finger prick blood sample, with results in five minutes or less. In the
meantime, SiPhox Health has launched a mail-in blood collection kit that measures 17
biomarkers for inflammation, metabolic, hormonal and cardiovascular health.
“SiPhox’s goal is to create category-defining health tracking products starting with the
SiPhox Home, which is a 100-fold improvement over existing blood diagnostics. Eventually,
our technology will enable the ultimate wearable device for measuring proteins, hormones,
and small molecules continuously,” said Michael Dubrovsky, SiPhox Health co-founder and
Chief Product Officer. “Every cell in the human body is a much more advanced sensor than
anything on the market today, showing we are nowhere near the physical limits for
performance and miniaturization in diagnostics.”
“The rapid growth in telehealth and home health sectors necessitates a new paradigm in
diagnostics. SiPhox Health’s fast and accurate at-home testing is poised to change the patient
journey for employers, pharma, insurers and health systems,” said Srini Ananth, managing
director at Intel Capital. "Investments in silicon photonics over the past two decades for the
datacom and telecom industry have enabled the massive scaling of the internet and cloud
computing. This has set the stage for startups like SiPhox to apply silicon photonics
technology to new frontiers. We are highly impressed with their technology and approach to
tackling this opportunity.”
